Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
Nuclea's Former CEO Attempting to Buy Company's Assets in Bankruptcy
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.
Nuclea, IRCM Partner to Validate Mass Spec Diabetes Assays
Under the partnership the two companies will develop assays for insulin, proinsulin, and c-peptide on clinical sample cohorts at both Nuclea and IRCM's facilities.
The company will focus largely on applying mass spec to relatively established protein markers for which existing immunoassay-based tests have poor performance.